There's a moment during many telehealth GLP-1 sign-ups that should feel like a medical encounter but feels instead like buying something online. You answer a series of questions. You click through some screens. You provide payment information. And then, often within minutes or hours, a prescription appears. At no point does someone sit you down — even virtually — and make sure you understand what you're agreeing to.
This is the informed consent problem in online weight loss, and it's one of the most important issues in telehealth GLP-1 care that most patients never think to question.
What Informed Consent Actually Requires
Informed consent is a legal and ethical requirement in medicine. Before prescribing a treatment, a healthcare provider must ensure the patient understands the nature of the treatment being offered, the expected benefits, the known risks and potential side effects, alternative treatment options, and what to expect if the patient declines treatment.
This isn't just a checkbox — it's a process. The provider must communicate this information in a way the patient can understand, and the patient must have the opportunity to ask questions and receive answers. Consent that's given without understanding isn't truly informed.
For GLP-1 medications specifically, informed consent should cover the difference between FDA-approved and compounded medications (if a compounded product is being prescribed), common side effects (nausea, constipation, diarrhea) and serious risks (pancreatitis, gallbladder disease, thyroid C-cell tumors), the boxed warning regarding medullary thyroid carcinoma, dose titration expectations and the timeline for results, the likelihood and implications of weight regain if the medication is discontinued, the importance of lifestyle modification alongside medication, and the total cost of treatment — not just the introductory price.
Where Telehealth Platforms Fall Short
The design choices that make telehealth convenient can also undermine informed consent when they're not handled carefully.
Asynchronous evaluations
Many GLP-1 telehealth platforms use asynchronous intake — the patient fills out a questionnaire, and a clinician reviews it without a live interaction. This model can be clinically appropriate for straightforward cases, but it makes genuine informed consent difficult. There's no opportunity for the patient to ask questions in real time, no way for the clinician to gauge whether the patient truly understands the information, and no natural pause in the process where the patient might reconsider.
Some platforms address this by including detailed educational content within the intake flow — videos explaining the medication, risk disclosures, and interactive acknowledgments. Others reduce informed consent to a scrollable block of text with a "I agree" button at the bottom, which most people click without reading.
Conversion-optimized design
Telehealth platforms are businesses, and many are designed with conversion optimization in mind — meaning the user experience is engineered to move patients from landing page to purchase as smoothly as possible. Every additional screen, every pause for information, every friction point is a place where a potential customer might drop off.
This creates a tension with informed consent. Genuine informed consent is inherently friction — it asks the patient to slow down, absorb information, and make a deliberate decision. A platform designed to minimize friction may inadvertently minimize consent.
Legal scholars have noted this dynamic. When the patient experience starts to resemble online shopping, there's a real risk that legal consent becomes confused with efficient checkout. The question isn't whether the consent form exists, but whether the patient actually receives and understands material information before treatment begins.
Speed as a selling point
Some platforms advertise speed as a feature — "Get your prescription in as little as 20 minutes" or "Start treatment today." Speed isn't inherently problematic, but it does raise questions about whether there was adequate time for information exchange. A medical decision should take as long as it needs to take, not as little time as the platform can manage.
Reporting has highlighted cases where patients received prescriptions within minutes without ever speaking to a clinician, and without being clearly informed about what they were receiving. One consumer profiled by a TV news outlet didn't realize she was injecting a compounded — not FDA-approved — version of semaglutide until a reporter explained it to her.
What Good Informed Consent Looks Like in Telehealth
Informed consent in a telehealth setting doesn't need to look identical to in-person consent. But it does need to achieve the same outcome: a patient who understands their treatment and makes a genuine choice.
Elements of well-designed telehealth informed consent include:
Clear, plain-language education. Information about the medication, its risks, and its alternatives should be presented in language that doesn't require a medical degree to understand. Medical jargon, dense legal text, and fine print all work against comprehension.
Interactive elements. Instead of a passive text block, effective consent might include short educational videos, knowledge-check questions ("Based on what you've read, which of the following is true about compounded medications?"), or interactive disclosures that require the patient to engage with specific risk categories.
An opportunity for questions. Even in an asynchronous model, patients should have a clear, easy-to-use channel for asking questions before consenting — and the questions should be answered by a clinician, not a chatbot or FAQ page.
Explicit distinction between FDA-approved and compounded products. If the platform offers compounded medications, the consent process should clearly state that these are not FDA-approved, not reviewed by the FDA for safety or effectiveness, and not the same as generic drugs. This shouldn't be buried in terms of service.
Transparent cost disclosure. Informed consent extends to financial consent. A patient who agrees to treatment based on a $149/month advertised price, without understanding that their cost will rise to $299+/month at maintenance dose, has not been fully informed.
A deliberate pause. The best telehealth consent processes build in a moment — even a brief one — where the patient is asked to confirm their decision before payment is processed. This is the digital equivalent of a doctor asking, "Do you have any questions before we proceed?"
Your Rights as a Patient
Regardless of how a telehealth platform designs its intake, you have certain rights that don't change just because the interaction is online:
You have the right to know what medication you're being prescribed — including whether it's FDA-approved or compounded, who manufactures or compounds it, and what it contains.
You have the right to understand the risks — not in legalese, but in plain language. If you don't understand something, you have the right to ask and receive a clear answer.
You have the right to know about alternatives. If a platform only offers one product, that doesn't mean it's the only option that exists. You have the right to know about other medications, other formulations, and other approaches to weight management.
You have the right to take your time. No legitimate medical decision requires you to decide immediately. If a platform creates artificial urgency — "Limited spots available" or "Price increases tomorrow" — that's a sales tactic, not a medical recommendation.
You have the right to say no. You can complete an intake process and decide not to proceed. You can start treatment and decide to stop. Informed consent is ongoing, not a one-time gate.
What You Can Do
Before consenting to GLP-1 treatment through any telehealth platform, take these steps:
Read the consent materials. Yes, actually read them. They contain information about risks and limitations that may not appear anywhere else on the platform. If the consent form is too long to read comfortably, that's a design problem — but the information still matters.
Ask at least one question. Even if you feel confident about proceeding, asking a question forces the platform to demonstrate that a real clinician is engaged in your care. If your question goes unanswered or gets a clearly automated response, that tells you something about the clinical depth behind the platform.
Understand the difference between medical evaluation and intake form. An intake form is data collection. A medical evaluation is a clinician applying their judgment to your specific situation. Both may happen digitally, but they're not the same thing. If all you experienced was a form, ask whether a clinician actually reviewed your information and made an individualized assessment.
Know what you're agreeing to financially. Consent to treatment includes consent to the cost. Make sure you understand not just the starting price, but the price at maintenance dose, any recurring fees, and the cancellation/refund policy.
The Bottom Line
Informed consent isn't just a legal requirement — it's a patient right that protects your autonomy and safety. When telehealth platforms design their intake processes to minimize friction, informed consent can become a casualty of efficiency. You deserve more than a checkbox.
The best telehealth platforms treat informed consent as a feature, not a barrier — an opportunity to build trust, demonstrate clinical seriousness, and ensure that every patient starts treatment with realistic expectations and genuine understanding. If your telehealth experience felt more like buying something than deciding something, it's worth asking whether you got the information you needed.